These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 12426511)

  • 1. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein.
    Cummins CL; Wu CY; Benet LZ
    Clin Pharmacol Ther; 2002 Nov; 72(5):474-89. PubMed ID: 12426511
    [No Abstract]   [Full Text] [Related]  

  • 2. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity.
    Kurnik D; Wood AJ; Wilkinson GR
    Clin Pharmacol Ther; 2006 Sep; 80(3):228-34. PubMed ID: 16952489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro.
    Mc Donnell CG; Shorten G; Van Pelt FN
    Anaesthesia; 2005 Aug; 60(8):747-53. PubMed ID: 16029222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The metabolism of midazolam and comparison with other CYP enzyme substrates during intestinal absorption: in vitro studies with rat everted gut sacs.
    Arellano C; Philibert C; Vachoux C; Woodley J; Houin G
    J Pharm Pharm Sci; 2007; 10(1):26-36. PubMed ID: 17498391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: some answers but still questions.
    Wilkinson GR
    Clin Pharmacol Ther; 2004 Aug; 76(2):99-103. PubMed ID: 15289786
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo.
    Ring BJ; Patterson BE; Mitchell MI; Vandenbranden M; Gillespie J; Bedding AW; Jewell H; Payne CD; Forgue ST; Eckstein J; Wrighton SA; Phillips DL
    Clin Pharmacol Ther; 2005 Jan; 77(1):63-75. PubMed ID: 15637532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.
    Gorski JC; Huang SM; Pinto A; Hamman MA; Hilligoss JK; Zaheer NA; Desai M; Miller M; Hall SD
    Clin Pharmacol Ther; 2004 Jan; 75(1):89-100. PubMed ID: 14749695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of various cytochrome P450 3A and P-glycoprotein modulators on the biliary clearance of bromosulphaphthalein in male wistar rats.
    Machavaram KK; Gundu J; Yamsani MR
    Pharmazie; 2004 Dec; 59(12):957-60. PubMed ID: 15638086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity.
    Rogers JF; Rocci ML; Haughey DB; Bertino JS
    Clin Pharmacol Ther; 2003 Mar; 73(3):153-8. PubMed ID: 12621380
    [No Abstract]   [Full Text] [Related]  

  • 11. Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered?
    Roedler R; Neuhauser MM; Penzak SR
    Ann Pharmacother; 2007 Apr; 41(4):653-8. PubMed ID: 17374625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.
    Wong M; Balleine RL; Collins M; Liddle C; Clarke CL; Gurney H
    Clin Pharmacol Ther; 2004 Jun; 75(6):529-38. PubMed ID: 15179407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats.
    Zhang W; Tan TM; Lim LY
    Drug Metab Dispos; 2007 Jan; 35(1):110-5. PubMed ID: 17050652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450-dependent metabolism of monensin in hepatic microsomes from chickens and turkeys.
    Henri J; Manceau J; Sanders P; Laurentie M
    J Vet Pharmacol Ther; 2008 Dec; 31(6):584-6. PubMed ID: 19000283
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans.
    Okudaira T; Kotegawa T; Imai H; Tsutsumi K; Nakano S; Ohashi K
    J Clin Pharmacol; 2007 Jul; 47(7):871-6. PubMed ID: 17585116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions.
    Stringer RA; Strain-Damerell C; Nicklin P; Houston JB
    Drug Metab Dispos; 2009 May; 37(5):1025-34. PubMed ID: 19196847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hepatic CYP3A activity in association with development of osteonecrosis of the femoral head].
    Kaneshiro Y; Takaoka K
    Clin Calcium; 2007 Jun; 17(6):902-9. PubMed ID: 17548930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption.
    Dey S; Gunda S; Mitra AK
    J Pharmacol Exp Ther; 2004 Oct; 311(1):246-55. PubMed ID: 15175422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
    Masica AL; Mayo G; Wilkinson GR
    Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six patterns of drug-drug interactions.
    Armstrong SC; Cozza KL; Sandson NB
    Psychosomatics; 2003; 44(3):255-8. PubMed ID: 12724509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.